AMP 110

Drug Profile

AMP 110

Alternative Names: AMP-110

Latest Information Update: 29 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amplimmune
  • Developer Daiichi Sankyo Company; MedImmune
  • Class Antirheumatics; Recombinant fusion proteins
  • Mechanism of Action T cell activation inhibitors; Th1 cell inhibitors; Th17 cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Rheumatoid arthritis
  • No development reported Autoimmune disorders

Most Recent Events

  • 29 Nov 2016 AMP 110 is still in phase I trials for Rheumatoid arthritis in USA
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Rheumatoid-arthritis in USA (IV, Infusion)
  • 28 Apr 2016 No recent reports on development identified - Preclinical for Autoimmune disorders in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top